Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896983939> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2896983939 endingPage "e123" @default.
- W2896983939 startingPage "e123" @default.
- W2896983939 abstract "To report early toxicity results of combination of brachytherapy and ultra-hypofractionated radiation therapy in a Phase II prospective trial. Forty-six patients with intermediate risk prostate cancer underwent LDR prostate brachytherapy using Pd-103 (100Gy) followed by ultra-hypofractionated, image-guided intensity modulated radiation therapy to a dose of 25Gy in 5 fractions delivered every other day. Eligibility included: clinical stage T2b/c or Gleason 7 or PSA 10-20ng/mL, prostate volume ≤ 60cc, and an IPSS ≤ 15. Patients were followed at 1, 3 and 6 months then every 6 months for two years. Post-treatment assessments include PSA, CTCAE 4.0 treatment-related toxicities, and patient-reported outcomes including IPSS. The primary endpoint of the study was was urinary toxicity at 12 months, which all patients have reached. A post-treatment biopsy was planned between 24-36 months. The trial was initiated in 11/2014 and completed accrual in 03/2017. We report acute toxicities in the first 24 patients who have reached 24 months of follow-up. Fifteen of 24 (63%) patients experienced acute grade 2 urinary toxicity which primarily consisted of urinary frequency, urgency and/or weak stream requiring medication. All were resolved at last followup except 1 patient with urinary frequency at time of this analysis. The average IPSS at baseline was 5.29 which peaked at 1m (average 13.9) and subsequently declined to an average of 9.7 at 12months and 5.4 at 24 months. In terms of rectal toxicity, 2 patients experienced grade 2 proctitis and rectal hemorrhage and 1 patient experienced a 3 grade toxicity (rectal ulcer), all of which were resolved with conservative management. The 12 and 24 month post-treatment PSA median nadirs were 0.57ng/mL and 0.25ng/mL, respectively. Fourteen patients had post-treatment surveillance biopsies, 13 of which were negative; one equivocal biopsy demonstrated adenocarcinoma with treatment effects. In this preliminary analysis of a prospective trial of LDR brachytherapy combined with hypofractionated IGRT, we demonstrate acceptable acute urinary and rectal toxicity. Post-treatment biopsies at 24-36m have been negative to date. Additional followup is needed to confirm these findings." @default.
- W2896983939 created "2018-10-26" @default.
- W2896983939 creator A5001940130 @default.
- W2896983939 creator A5012145979 @default.
- W2896983939 creator A5024318130 @default.
- W2896983939 creator A5049069950 @default.
- W2896983939 creator A5062947827 @default.
- W2896983939 creator A5070477028 @default.
- W2896983939 creator A5081611907 @default.
- W2896983939 creator A5089582082 @default.
- W2896983939 date "2018-11-01" @default.
- W2896983939 modified "2023-10-02" @default.
- W2896983939 title "A Phase II Trial of Low Dose Rate Brachytherapy Combined with Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiation Therapy for Clinically Localized, Intermediate Risk Prostate Cancer: A Preliminary Analysis" @default.
- W2896983939 doi "https://doi.org/10.1016/j.ijrobp.2018.07.330" @default.
- W2896983939 hasPublicationYear "2018" @default.
- W2896983939 type Work @default.
- W2896983939 sameAs 2896983939 @default.
- W2896983939 citedByCount "0" @default.
- W2896983939 crossrefType "journal-article" @default.
- W2896983939 hasAuthorship W2896983939A5001940130 @default.
- W2896983939 hasAuthorship W2896983939A5012145979 @default.
- W2896983939 hasAuthorship W2896983939A5024318130 @default.
- W2896983939 hasAuthorship W2896983939A5049069950 @default.
- W2896983939 hasAuthorship W2896983939A5062947827 @default.
- W2896983939 hasAuthorship W2896983939A5070477028 @default.
- W2896983939 hasAuthorship W2896983939A5081611907 @default.
- W2896983939 hasAuthorship W2896983939A5089582082 @default.
- W2896983939 hasConcept C121608353 @default.
- W2896983939 hasConcept C126322002 @default.
- W2896983939 hasConcept C126894567 @default.
- W2896983939 hasConcept C141071460 @default.
- W2896983939 hasConcept C168563851 @default.
- W2896983939 hasConcept C203092338 @default.
- W2896983939 hasConcept C2776235491 @default.
- W2896983939 hasConcept C2776547966 @default.
- W2896983939 hasConcept C2777416452 @default.
- W2896983939 hasConcept C2779134260 @default.
- W2896983939 hasConcept C2779478474 @default.
- W2896983939 hasConcept C2779810446 @default.
- W2896983939 hasConcept C2780192828 @default.
- W2896983939 hasConcept C2780479503 @default.
- W2896983939 hasConcept C29730261 @default.
- W2896983939 hasConcept C509974204 @default.
- W2896983939 hasConcept C71924100 @default.
- W2896983939 hasConcept C77411442 @default.
- W2896983939 hasConceptScore W2896983939C121608353 @default.
- W2896983939 hasConceptScore W2896983939C126322002 @default.
- W2896983939 hasConceptScore W2896983939C126894567 @default.
- W2896983939 hasConceptScore W2896983939C141071460 @default.
- W2896983939 hasConceptScore W2896983939C168563851 @default.
- W2896983939 hasConceptScore W2896983939C203092338 @default.
- W2896983939 hasConceptScore W2896983939C2776235491 @default.
- W2896983939 hasConceptScore W2896983939C2776547966 @default.
- W2896983939 hasConceptScore W2896983939C2777416452 @default.
- W2896983939 hasConceptScore W2896983939C2779134260 @default.
- W2896983939 hasConceptScore W2896983939C2779478474 @default.
- W2896983939 hasConceptScore W2896983939C2779810446 @default.
- W2896983939 hasConceptScore W2896983939C2780192828 @default.
- W2896983939 hasConceptScore W2896983939C2780479503 @default.
- W2896983939 hasConceptScore W2896983939C29730261 @default.
- W2896983939 hasConceptScore W2896983939C509974204 @default.
- W2896983939 hasConceptScore W2896983939C71924100 @default.
- W2896983939 hasConceptScore W2896983939C77411442 @default.
- W2896983939 hasIssue "3" @default.
- W2896983939 hasLocation W28969839391 @default.
- W2896983939 hasOpenAccess W2896983939 @default.
- W2896983939 hasPrimaryLocation W28969839391 @default.
- W2896983939 hasRelatedWork W2048085960 @default.
- W2896983939 hasRelatedWork W2083802215 @default.
- W2896983939 hasRelatedWork W2085529113 @default.
- W2896983939 hasRelatedWork W2105549398 @default.
- W2896983939 hasRelatedWork W2123819582 @default.
- W2896983939 hasRelatedWork W2165532162 @default.
- W2896983939 hasRelatedWork W2348716247 @default.
- W2896983939 hasRelatedWork W2534674868 @default.
- W2896983939 hasRelatedWork W4286561766 @default.
- W2896983939 hasRelatedWork W4308148977 @default.
- W2896983939 hasVolume "102" @default.
- W2896983939 isParatext "false" @default.
- W2896983939 isRetracted "false" @default.
- W2896983939 magId "2896983939" @default.
- W2896983939 workType "article" @default.